Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.
JH-X-119-01 is a covalent inhibitor of IL-1 receptor-associated kinase 1 (IRAK1; IC50 = 9 nM).1 It is selective for IRAK1 over IRAK4 (IC50 = >10,000 nM). JH-X-119-01 is cytotoxic against a panel of mutant MyD88-expressing Waldenstrom’s macroglobulinemia (WM), ABC subtype diffuse large B cell lymphoma (DLBCL), and lymphoma cells (EC50s = 0.59-9.72 µM). It has a synergistic cytotoxic effect in MyD88-mutant-expressing BCWM.1 WM and TMD8 ABC DLBCL cells when used in combination with ibrutinib (Item No. 16274). JH-X-119-01 (5 and 10 mg/kg) also reduces lung injury and increases survival in a mouse model of LPS-induced sepsis.2
WARNING This product is not for human or veterinary use.
1. Discovery of a selective, covalent IRAK1 inhibitor with antiproliferative activity in MYD88 mutated B-
2. Selective inhibition of interleukin-